MALIGNANT PLEURAL MESOTHELIOMA
Clinical trials for MALIGNANT PLEURAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT PLEURAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for MALIGNANT PLEURAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
5-Day radiation blitz tested for deadly lung cancer
Disease control OngoingThis study is testing a shorter, 5-day course of targeted radiation for people with malignant pleural mesothelioma, a serious cancer often linked to asbestos. The treatment is given after surgery or a diagnostic biopsy. The main goal is to see if this faster schedule is safe and …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo treatment tested before surgery for aggressive cancer
Disease control OngoingThis early-stage study is checking if it's safe and practical to give a drug called nivolumab (an immunotherapy) along with standard chemotherapy before surgery for a type of lung cancer called malignant pleural mesothelioma. The main goal is to see if this combination treatment …
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo treatment tested for tough chest cancer
Disease control OngoingThis early-stage study is testing whether combining a targeted radiation technique called IMPRINT with the immunotherapy drug pembrolizumab is safe for people with advanced malignant pleural mesothelioma. Researchers will first find the highest radiation dose that causes few or m…
Matched conditions: MALIGNANT PLEURAL MESOTHELIOMA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC